Form 4: Alaunos Therapeutics CEO Granted 130,000 Stock Options

Alaunos Therapeutics, Inc. has granted its Chief Executive Officer, Holger Weis, 130,000 employee stock options with an exercise price of $5.02.

Summary

• Holger Weis, Chief Executive Officer and Director of Alaunos Therapeutics, Inc. (TCRT), was granted 130,000 employee stock options.
• The transaction date for this grant was July 2, 2025.
• The exercise price for these stock options is $5.02 per share.
• The options have an expiration date of July 1, 2035.
• 25% of the granted options will vest and become exercisable immediately upon grant.
• The remaining balance of the options will vest in substantially equal quarterly installments over a three-year period, commencing on the start date with the first vesting date being October 2, 2025.
• Vesting is contingent upon the holder's continuous employment through each vesting date.
• The option grant is subject to the terms and conditions of the Company's 2020 Equity Incentive Plan and a Stock Option Agreement.
• Following this transaction, Holger Weis beneficially owns 130,000 derivative securities directly.

Sentiment

Score: 6

Explanation: The grant of stock options to the CEO is a standard compensation practice that aligns management incentives with shareholder interests, which is generally viewed as a positive or neutral event. It does not indicate any immediate operational or financial changes, but rather a long-term incentive.

Positives

• The grant of stock options to the CEO aligns management's interests with those of shareholders, incentivizing long-term company performance.
• The options are granted under the Company's 2020 Equity Incentive Plan, indicating a structured approach to executive compensation.

Future Outlook

The vesting schedule for the stock options, extending over three years, indicates a long-term incentive structure for the CEO, aligning future performance with compensation.

Industry Context

The granting of stock options to executive leadership is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive compensation packages designed to attract, retain, and incentivize top talent by aligning their financial interests with long-term shareholder value creation.

Comparison to Industry Standards

• The use of stock options as a form of executive compensation is a standard practice across the biotechnology sector, comparable to compensation structures at companies like Moderna, BioNTech, or Gilead Sciences, which frequently utilize equity incentives to motivate leadership.
• The vesting schedule, with an immediate portion and subsequent quarterly installments over three years, is a common structure designed to ensure continuous employment and sustained performance, similar to practices observed in many growth-oriented tech and biotech firms.

Corporate Governance

Related Party Transactions

• The grant of 130,000 employee stock options to Holger Weis, the Chief Executive Officer and a Director, constitutes a related party transaction as it involves compensation to a key management personnel.

Stakeholder Impact

• Shareholders: The grant aims to align the CEO's financial interests with long-term shareholder value creation, potentially leading to improved company performance.
• Employees: This transaction is part of the company's broader equity incentive plan, which can set a precedent for performance-based compensation across the organization.

Next Steps

• The options will begin vesting in quarterly installments starting October 2, 2025, subject to the CEO's continuous employment.
• The CEO may exercise vested options at the $5.02 price per share at any time before the expiration date of July 1, 2035.

Key Dates

Keywords

Alaunos Therapeutics, TCRT, Holger Weis, Stock Options, Employee Stock Option, Executive Compensation, SEC Form 4, Insider Transaction, Equity Incentive Plan, Biotechnology